Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gain Therapeutics (GANX)
NASDAQ:GANX
Gain Therapeutics (GANX) Stock Price & Analysis
149 Followers
GANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.00 - $5.45
Previous Close$2.54
Volume106.80K
Average Volume (3M)123.17K
Market Cap
$45.85M
Enterprise Value$30.08M
Total Cash (Recent Filing)$16.79M
Total Debt (Recent Filing)$1.03M
Price to Earnings (P/E)-1.5
Beta0.71
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding16,219,709
10 Day Avg. Volume126,646
30 Day Avg. Volume123,172
Standard Deviation0.17
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue545.21
Enterprise Value/Gross Profit545.21
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$9.33Price Target Upside271.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Gain Therapeutics News
Ownership Overview
1.88% Insiders
1.67% Mutual Funds
5.13% Other Institutional Investors
91.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GANX FAQ
What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $2.00 and its highest was $5.45 in the past 12 months.
What is Gain Therapeutics’s market cap?
Currently, no data Available
When is Gain Therapeutics’s upcoming earnings report date?
Gain Therapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 88 days.
How were Gain Therapeutics’s earnings last quarter?
Currently, no data Available
Is Gain Therapeutics overvalued?
According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
Does Gain Therapeutics pay dividends?
Gain Therapeutics does not currently pay dividends.
What is Gain Therapeutics’s EPS estimate?
Gain Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gain Therapeutics have?
Gain Therapeutics has 18,051,980 shares outstanding.
What happened to Gain Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Gain Therapeutics?
Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 2M.
---
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (271.71% Upside)
$9.33 (271.71% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $115.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.77%
12-Months-Change
Fundamentals
Return on Equity
-141.57%
Trailing 12-Months
Asset Growth
-22.78%
Trailing 12-Months
Company Description
Gain Therapeutics
Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
---
GANX Stock 12 Month Forecast
Average Price Target
$9.33
▲(271.71% Upside)
Technical Analysis
---